Immunotherapy Press Release
|06/22/2020 - 14:16||
Study led by City of Hope, TGen shows new way of identifying tumor response to immunotherapy
DUARTE, Calif. — Scientists at City of Hope, working in collaboration with researchers at Translational Genomics Research Institute (TGen) and other colleagues across the country, have found that the actions of circulating immune cells — namely how they differentiate and signal — at the start of immunotherapy treatment for cancer can inform how a patient will respond to the therapy. The team’s findings will publish this week in the Proceedings of the National Academy of Sciences of the United States of America.
|City of Hope Na...|
|06/22/2020 - 12:40||
OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
PENNINGTON, N.J. and SAN DIEGO, June 22, 2020 / / -- OncoSec Medical Incorporated (the "Company" or "OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today presented new data further demonstrating the power of OncoSec's next-generation interleukin-12 (IL-12) plasmid (TAVO PLUS ) therapeutic when combined with a T cell stimulator (TAVO PLUS -CD3) or an enhanced chemokine gradient (TAVO PLUS -CXCL9).
|06/22/2020 - 12:22||
Celsion Corporation Announces Pricing of $10 Million Underwritten Offering of Common Stock
Lawrenceville, NJ , June 22, 2020 ( ) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the entry into an underwriting agreement relating to the sale of 2,666,667 shares of its common stock at an offering price of $3.
|06/19/2020 - 18:48||
IMV Files Preliminary Base Shelf Prospectus to Replace Expiring Base Shelf Prospectus
The Shelf Prospectus and corresponding shelf registration statement, when made final or effective, will allow IMV to offer up to US$125,000,000 of common shares, preferred shares, subscription receipts, warrants, options or any combination thereof during the 25-month period that the Shelf Prospectus will be effective. The Shelf Prospectus will enable IMV to potentially access new capital if and when needed. The amount and timing of any future offerings will be based on the Company’s financial requirements and market conditions at the time.
|06/18/2020 - 14:06||
Research on cancer, fungal infection, vision loss funded by Michigan Drug Discovery
Three innovative drug discovery projects targeting cancer, fungal infection and vision loss are moving forward at the University of Michigan with early-stage funding from Michigan Drug Discovery.
|University of M...|
|06/17/2020 - 14:19||
Jedd D. Wolchok, MD, PhD, Honored With 2020 AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research
PHILADELPHIA — The American Association for Cancer Research (AACR) is recognizing Jedd D. Wolchok, MD, PhD, with the 2020 AACR-Joseph Burchenal Award for Outstanding Achievement in Clinical Cancer Research.
|06/15/2020 - 18:08||
UCLA receives nearly $14 million from NIH to investigate gene therapy to combat HIV
UCLA researchers and colleagues have received a $13.65 million grant from the National Institutes of Health to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV.
|06/15/2020 - 05:35||
IMV Announces Leading Independent Proxy Advisory Firms Recommend Shareholders Vote FOR All Resolutions at Upcoming Annual and Special Meeting
ISS and Glass Lewis are both leading independent proxy advisory firms who, among other things, provide proxy voting recommendations to pension funds, investment managers, mutual funds and other institutional shareholders.
|06/12/2020 - 16:59||
CRI Celebrates a Future #Immune2Cancer on June 12
On Friday, June 12, 2020, the global cancer community joined the Cancer Research Institute’s annual awareness day to amplify the lifesaving potential of immunotherapy. Scientists wore lab coats; doctors wore white coats; and patients, caregivers, and advocates wore white in honor of their cancer-fighting white blood cells.
|06/11/2020 - 17:11||
Two new, powerful small molecules may be able to kill cancers that other therapies cant
DUARTE, Calif. — City of Hope scientists have identified and developed two potent small molecules that appear to suppress tumor growth in multiple cancers even when other treatments cease to work, possibly due to the development of drug resistance.
|City of Hope Na...|
|06/11/2020 - 04:26||
Grifols starts production of its hyperimmune immunoglobulin as a potential passive immune therapy against COVID-19
Grifols continues to lead initiatives to combat COVID-19 with the development of the first specific drug.
|06/11/2020 - 04:11||
City of Hope signs licensing agreement with Scopus BioPharma Inc. to develop novel, targeted immuno-oncology gene therapy
DUARTE, Calif. — City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, has signed an exclusive, worldwide licensing agreement with Scopus BioPharma Inc., a biopharmaceutical company focused on novel therapeutics for serious diseases with significant unmet medical needs. Scopus will further develop and plans to commercialize a City of Hope first-in-class, targeted immuno-oncology gene therapy.
|City of Hope Na...|
|06/11/2020 - 03:10||
BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1 Synthesized by AMRI
Under the first agreement, Neurotrope will transfer to BryoLogyx the right to develop bryostatin‑1 for the potential treatment of CD22+ B-cell acute lymphoblastic leukemia (ALL). Relapsed ALL in CD22 CAR-T treated patients has been associated with reduced CD22 antigen density. Bryostatin-1 has been shown to increase CD22 expression levels in leukemia patients, and in a mouse model, resulted in improved treatment response and durability. Neurotrope will also transfer to BryoLogyx the Investigational New Drug (“IND”) application that is in development.
|06/11/2020 - 01:22||
HUS and University of Helsinki received funding for a new clinical breast cancer study
A Finnish Jane and Aatos Erkko Foundation awarded 1,5 million euros to support a VeMA clinical breast cancer study scheduled to start in HUS Comprehensive Cancer Center already this year. The clinical trial is among the first in the world having a biologic rationale rooted to MYC oncoprotein's apoptosis promoting function.
|06/09/2020 - 14:39||
City of Hope scientists showcase new findings at the 2020 AACR Virtual Annual Meeting II
DUARTE, Calif. — City of Hope scientists will showcase research at the AACR Virtual Annual Meeting II that could one day lead to real-time diagnostic imaging and leading-edge genomic profiling that improve health outcomes for cancer patients, and much more.
|City of Hope Na...|
|06/08/2020 - 06:37||
IMV to Present at Raymond James' Human Health Innovation Conference
A live webcast of this presentation will be available under “ Events, Webcasts and Presentations " in the investors section of the IMV website and a replay will be available approximately one hour after the presentation. Afterwards, it will be available for approximately 30 days.
|06/04/2020 - 05:49||
OncoSec to Present at Virtual Summer Investor Summit
PENNINGTON, N.J. and SAN DIEGO, June 4, 2020 / / -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer of OncoSec, will present a company overview at the Virtual Summer Investor Summit on Tuesday, June 9 th at 9:45 a.m.
|06/01/2020 - 18:30||
Glenn D. Steele, Jr., M.D., Ph.D., renowned health care leader and innovator, named chair of City of Hope Board of Directors
DUARTE, Calif. — Preeminent health care innovator and leader Glenn D. Steele Jr., M.D., Ph.D., has been elected the new board chair of City of Hope, the world-renowned cancer and diabetes research and treatment center, effective June 1. He joined the City of Hope Board of Directors in January 2016. Prior to becoming chair, he was chair of the Executive Compensation and Governance Committee from 2018-2020.
|City of Hope Na...|
|05/31/2020 - 19:38||
CELLULAR IMMUNOTHERAPY ADVANCES AT ASCO20
CAR T cell therapy targeting the CD19 marker has already made an impact in B cell blood cancers, particularly leukemia and lymphoma . As noted by Suzanne Lentzsch, Ph.D. , a CRI CLIP Investigator at Columbia University Medical Center, there was a 45 percent decrease in stem cell transplants among lymphoma patients with diffuse large B cell lymphoma in 2018 compared to 2017, which she suggested was likely due to the FDA approval of the first CAR T cell immunotherapy for lymphoma in 2017.
|05/29/2020 - 10:59||
Imfinzi showed a sustained overall survival benefit in 1st-line extensive-stage small cell lung cancer in the Phase III CASPIAN trial
The safety and tolerability for Imfinzi plus chemotherapy was consistent with the known safety profile of these medicines. Results showed 62.3% of patients experienced a Grade 3 or 4 adverse event with Imfinzi plus chemotherapy (all causes) versus 62.8% with chemotherapy alone. The percentage of patients discontinuing treatment (all causes) was 10.2% for Imfinzi plus chemotherapy and 9.4% for chemotherapy alone.
|05/27/2020 - 11:45||
OncoSec Strengthens IP Portfolio with Three New Patents Covering TAVO and Its Electroporation Gene Delivery System
PENNINGTON, N.J. and SAN DIEGO, May 27, 2020 / / -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced Notices of Allowance for three new patent applications covering its interleukin-12 (IL-12) based immunotherapy platform, including its lead product candidate TAVO™ and next-generation product candidate TAVO PLUS , and electroporation gene delivery system.
|05/27/2020 - 04:37||
Biodesix Presents Numerous Research Findings at ATS, ASCO, and AACR Virtual Conferences
Clinical Data Offer Meaningful Diagnostic Information for Patients in the Lung Cancer Continuum of Care.
|05/27/2020 - 00:46||
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
Live webcasts of the fireside chat and presentation may be accessed from the Events & Presentation section of the Bellicum website. An archived version of each webcast will be available for replay immediately following the event.
|05/22/2020 - 08:19||
Patients with Metastatic Pancreatic Cancer and DNA Repair Defects May Have Improved Survival after Platinum-based Chemotherapy
PHILADELPHIA – Patients with metastatic pancreatic cancer who had germline or somatic mutations in DNA repair genes had better clinical outcomes after platinum-based chemotherapy, as compared with patients without these mutations, according to results from a study published in Clinical Cancer Research , a journal of the American Association for Cancer Research.
|05/22/2020 - 00:14||
Enhertu granted Orphan Drug Designation in the US for gastric cancer
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.